{"filings":[{"id":2494166,"accession_number":"0001104659-26-101531","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-08-26T20:30:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health reports record FY2026 results, raises FY2027 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $396.7M (+5% YoY); diluted EPS $0.53 (+26%); adjusted EPS $0.85 (+35%).","FY2026 net sales $1,518.1M (+17%); net income $99.7M; adjusted EBITDA $255.0M (+39%).","FY2027 guidance: net sales $1.55-1.60B, adjusted EBITDA $258-268M, adjusted net income $140-147M.","Plans to close Chicago Heights manufacturing facility; production ceases summer 2027, ~100 employees affected.","Regulatory uncertainty on virginiamycin in Brazil; guidance assumes minimal sales, potential upside if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":2.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1518093000.0,"consensus_period":"2026-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1913676,"accession_number":"0001104659-26-087544","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-07-28T20:16:08+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable Sept 23, 2026","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on September 23, 2026, to stockholders of record at close of business on September 2, 2026.","Dividend declared by Board of Directors on July 28, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1306236,"accession_number":"0001104659-26-078323","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-06-26T21:07:54+00:00","items":["5.02"],"status":"ready","headline":"Phibro Animal Health appoints Daniel Bendheim as CEO effective July 1, 2026, with performance-based RSU grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Bendheim appointed CEO & President effective July 1, 2026; base salary $850k, target bonus 50% of salary.","Granted 300,000 performance-based RSUs vesting based on 90-day average stock price from $70 to $100+ by June 30, 2031.","Severance: 18 months COBRA if terminated without cause; 6 months base salary for death/disability.","Employment agreement includes confidentiality, non-compete, non-solicitation, non-disparagement covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91071,"accession_number":"0001104659-26-056316","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health Q3 FY2026: Sales $383.5M (+10%), Adj. EBITDA $60.8M (+11%); Guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $383.5M, +10% YoY; Animal Health segment +13% to $291.2M, driven by MFA portfolio, nutritional specialties, vaccines.","Net income $24.0M, +15%; diluted EPS $0.59; adjusted diluted EPS $0.76, +19% YoY.","Updated FY2026 guidance: net sales $1.46B-$1.50B (14% growth), adjusted EBITDA $247M-$255M (37% growth).","Post-quarter: expanded revolver by $125M to $435M; announced Sustainable Solutions Platform with VERRATAIN; Brazil regulatory development on antimicrobials noted.","Gross margin improved 270 bps to 32.8%; free cash flow $12.8M trailing twelve months; leverage 3.1x."],"consensus_eps_estimate":null,"consensus_eps_actual":1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":1121346000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91070,"accession_number":"0001104659-26-055699","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12/share quarterly dividend, payable June 24, 2026","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on June 24, 2026, to stockholders of record at close of business on June 3, 2026.","Dividend amount unchanged from prior quarter; no change in rate disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91069,"accession_number":"0001104659-26-052956","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Phibro Animal Health expands revolving credit facility by $125M to $435M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolver increased from $310M to $435M via Amendment No. 1 dated April 28, 2026.","New lenders include Bank of America, Citibank, BMO, Compeer Financial, and others.","Upfront fee of 0.15% of new commitments paid to incremental lenders.","Proceeds available for general corporate purposes under the existing credit agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91068,"accession_number":"0001104659-26-049485","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Brazilian MAPA bans Phibro's virginiamycin and bacitracin growth promoters; 180-day transition","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MAPA Ordinance 1617 prohibits import, manufacture, marketing and use of antimicrobial feed additives including virginiamycin and bacitracin for growth promotion.","Transition period of 180 days from April 27, 2026; products can still be sold under current labels during that time.","Phibro expects new therapeutic registrations for virginiamycin in cattle and broilers during transition; bacitracin already has therapeutic claims.","Company expects limited impact on fiscal year 2026 results; also launching PhibroVet digital prescription platform.","Additional details to be provided on May 7, 2026 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91067,"accession_number":"0001104659-26-043188","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Joyce J. Lee resigns from Phibro Animal Health Board, effective April 15, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joyce J. Lee, a Class II Director, informed the Company of her resignation effective April 15, 2026.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No replacement has been announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100973,"accession_number":"0001104659-26-010345","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Q2 net sales up 21% to $374M; raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $373.9M (+21% YoY); net income $27.5M vs $3.2M; diluted EPS $0.67 vs $0.08.","Adjusted diluted EPS $0.87 (+58% YoY); adjusted EBITDA $68.1M (+41% YoY).","Animal Health sales +26% to $290M, driven by $57.5M incremental MFA portfolio revenue.","FY2026 guidance raised: net sales $1.45-1.50B, adjusted EBITDA $245-255M, adjusted EPS $2.93-3.10.","Gross margin improved 260 bps to 35.5%; 3.1x gross leverage ratio; free cash flow $47.3M TTM."],"consensus_eps_estimate":null,"consensus_eps_actual":1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":737803000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100972,"accession_number":"0001104659-26-009739","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable March 25","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock declared.","Payable on March 25, 2026 to stockholders of record as of March 4, 2026.","Dividend rate unchanged from previous quarter; continues regular quarterly payout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117304,"accession_number":"0001104659-25-122556","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Phibro Animal Health Announces CEO Transition: Jack Bendheim to Executive Chairman, Dani Bendheim to CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack C. Bendheim will resign as CEO and President effective July 1, 2026, and assume the new role of Executive Chairman.","Daniel (Dani) Bendheim, age 53, current EVP Corporate Strategy, will become CEO and President on July 1, 2026.","Dani Bendheim has been with Phibro since 1997 and served as VP Business Development, President Performance Products, and EVP Corporate Strategy.","Jack Bendheim, son of founder, will continue as Chairman of the Board; the Board unanimously supports the transition.","A press release announcing the leadership change was issued on December 18, 2025, and furnished as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117303,"accession_number":"0001104659-25-107064","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Phibro Q1 net sales up 40% to $363.9M; raises FY2026 adjusted EBITDA guidance to $230-240M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $363.9M (+40% YoY); net income $26.5M ($0.65 diluted EPS) vs $7.0M ($0.17) prior year.","Adjusted diluted EPS $0.73 (doubled from $0.35); adjusted EBITDA $61.9M (+$31.2M YoY).","Animal Health sales rose 55% to $283.5M, driven by acquired MFA portfolio (+$80.5M incremental).","FY2026 guidance: Adjusted EBITDA raised to $230-240M (28% growth); net sales reaffirmed $1.43-1.48B.","Company launched Restoris™ dental gel for dogs; annual meeting reelected all director nominees and approved say-on-pay every 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":363893000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117302,"accession_number":"0001104659-25-106292","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend payable Dec 17, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on December 17, 2025 to holders of record at close on November 26, 2025.","Dividend rate unchanged from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133739,"accession_number":"0001558370-25-011778","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health Q4 net sales up 39% to $378.7M; FY2026 guidance sees 25% adj. EBITDA growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $378.7M (+39% YoY), net income $17.2M vs $0.8M, adj. diluted EPS $0.57 (+39%).","FY net sales $1,296.2M (+27%), adj. EBITDA $183.7M (+65%), adj. diluted EPS $2.09 (+76%).","Zoetis MFA portfolio contributed $94.5M incremental revenue in Q4 and $208.2M for full year.","FY2026 guidance: net sales $1.43-1.48B, adj. EBITDA $225-235M (25% growth), adj. EPS $2.52-2.70.","Gross leverage 3.1x as of June 30, 2025; free cash flow $41.8M for the year."],"consensus_eps_estimate":null,"consensus_eps_actual":1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1296215000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133738,"accession_number":"0001104659-25-071746","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable Sept 24","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Dividend payable September 24, 2025, to holders of record at close on September 3, 2025.","Declaration by Board of Directors on July 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150455,"accession_number":"0001558370-25-006760","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health Q3 net sales up 32% to $347.8M; Adj EBITDA +85%; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $347.8M (+32% YoY); net income $20.9M (+$12.5M); diluted EPS $0.51 (+$0.30).","Adjusted EBITDA $54.9M (+85% YoY); adjusted diluted EPS $0.63 (+$0.32).","Animal Health segment sales +42% driven by Zoetis MFA acquisition; legacy Animal Health flat.","Updated FY2025 guidance: net sales $1.26B-$1.29B, Adj EBITDA $177M-$183M (62% growth at midpoint).","Gross leverage ratio 3.0x; free cash flow $49.1M for trailing twelve months."],"consensus_eps_estimate":0.635,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":917518000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150454,"accession_number":"0001104659-25-045063","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable June 25, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on June 25, 2025, to stockholders of record at close of business on June 4, 2025.","Dividend declared by the Board of Directors on May 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169428,"accession_number":"0001558370-25-000661","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Q2 net sales up 24% to $309M; adjusted EPS $0.54 (+64% YoY); raises FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $309.3M (+24% YoY); Animal Health up 33% on Zoetis MFA acquisition added $36.7M.","Adjusted EBITDA $48.2M (+64% YoY); gross margin up 140 bps to 32.9%.","Net income $3.2M vs $1.3M prior year; adjusted net income $21.9M (+$8.5M).","Updated FY2025 guidance: net sales $1.25-1.30B, adjusted EBITDA $172-180M (58% growth midpoint).","Gross leverage 3.1x; total debt $760.3M; cash $67.1M; free cash flow $15.3M trailing 12M."],"consensus_eps_estimate":0.5304,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":569693000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169427,"accession_number":"0001104659-25-009123","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12/share quarterly dividend","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.12 per share on Class A and Class B common stock declared.","Payable March 26, 2025 to holders of record as of March 5, 2025.","No change from prior quarterly dividend rate; routine declaration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169426,"accession_number":"0001104659-25-005659","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Phibro Animal Health appoints Joyce J. Lee to board as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joyce J. Lee appointed as Class II independent director effective January 21, 2025, filling a vacancy.","Board expands to nine directors, six of whom are independent.","Ms. Lee most recently served as President of Cobb Vantress; prior exec roles at Elanco, Bayer Animal Health, Zoetis.","She will receive standard non-employee director compensation and has entered a director indemnification agreement.","Ms. Lee is expected to stand for election at the 2027 Annual Meeting of Stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169425,"accession_number":"0001558370-25-000053","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K/A","filed_at":"2025-01-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Phibro discloses Zoetis MFA portfolio audited financials: $407.6M revenue in FY2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired MFA portfolio had $407.6M revenue & $91.2M revenue less direct expenses in 2023; up from $59.9M in 2022.","Cost of sales was $284.3M in 2023 vs $310.3M in 2022; gross margin improved to 30.3% from 23.9%.","Total assets acquired as of Dec 2023: $334M; liabilities assumed: $24.5M; net assets ~$309.5M.","Transaction closed Oct 31, 2024 for $350M subject to adjustments; includes six manufacturing plants.","Pro forma financials filed for year ended June 30, 2024; combined entity impact not yet quantified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186480,"accession_number":"0001104659-24-116790","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Phibro Animal Health President of North America Region retiring; Todd Armstrong promoted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rob Aukerman retiring as President, North America Region effective Dec 31, 2024.","Aukerman to remain in advisory capacity through June 30, 2025 for transition.","Todd Armstrong, VP of US Ruminant Business since 2020, promoted to President effective Jan 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186479,"accession_number":"0001558370-24-014663","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Phibro Q1 net sales $260.4M (+13% YoY), net income $7.0M vs loss; updates FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $260.4M (+13% YoY); net income $7.0M vs net loss $8.0M; diluted EPS $0.17 vs -$0.20.","Adjusted EBITDA $30.7M, +64% YoY; adjusted diluted EPS $0.35 vs $0.14 prior year.","Updated FY2025 guidance: net sales $1.05B-$1.10B; Adjusted EBITDA $124M-$132M (15% growth).","Discontinued atopic dermatitis project; expects ~$200M sales from Zoetis MFA portfolio in FY2025.","Gross margin improved 280 bps to 32.1%; interest expense up $3.1M due to refinancing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":260432000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186478,"accession_number":"0001104659-24-114319","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable Dec 18","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on December 18, 2024; record date November 27, 2024.","Dividend rate unchanged; no increase or decrease announced.","Payment marks regular quarterly distribution to shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186477,"accession_number":"0001104659-24-113064","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.01","9.01","2.03","7.01"],"status":"ready","headline":"Phibro completes $350M acquisition of Zoetis' medicated feed additive portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired >37 product lines across ~80 countries, six manufacturing sites in US, Italy, China, and >300 employees.","Funded with $350M cash: $189M Delayed Draw Term A-1 Loans and $161M A-2 Loans under existing credit agreement.","Expected to boost profitability, EBITDA margin, and be accretive to adjusted EPS; more details on Nov 7 Q1 call.","Portfolio complements Phibro's vaccines, nutritional specialties, and mineral nutrition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203066,"accession_number":"0001558370-24-012519","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Q4 net sales up 7% to $273.2M; FY2025 guidance sees 10% adjusted EBITDA growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net income of $0.8M ($0.02 EPS) vs $11.5M ($0.28 EPS) YoY; adjusted EPS $0.41 (+10%).","Full-year net sales $1,017.7M (+4%); adjusted EBITDA $111.2M (-1%); adjusted EPS $1.19 (-1%).","FY2025 guidance: net sales $1.04B-$1.09B, adjusted EBITDA $118M-$126M, adjusted EPS $1.22-$1.37.","Free cash flow $46.4M; total debt $489.1M; cash & short-term investments $114.6M; gross leverage 4.4x.","Guidance excludes proposed Zoetis MFA acquisition; company notes strength in Q4 Animal Health segment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1017679000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203065,"accession_number":"0001104659-24-083979","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12/share quarterly dividend payable Sept 25, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock declared.","Dividend payable on September 25, 2024, to stockholders of record on September 4, 2024.","Dividend amount unchanged from prior quarter; no special or increased dividend announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203064,"accession_number":"0001104659-24-078557","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Phibro Animal Health enters $960M credit facility with Rabobank; delayed draw for Zoetis acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term A-1 loans total $351M (initial $162M + delayed $189M); Term A-2 loans total $299M.","Revolving credit commitment of $310M; Term A-1 and Revolver mature July 2029, Term A-2 July 2031.","Proceeds used to refinance existing debt, pay fees, and fund Zoetis Acquisition via delayed draw facilities.","Interest rates based on Net Leverage Ratio; commitment fees 0.20%-0.35% on undrawn commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219347,"accession_number":"0001558370-24-007371","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health Reports Q3 FY2024 Results; Updates Guidance, Plans Zoetis Acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales for Q3 ended March 31, 2024 were $263.2M, up 7% YoY; Animal Health segment grew 10%.","Adjusted EBITDA increased 9% to $29.7M; adjusted diluted EPS rose to $0.31 from $0.29.","Affirmed FY2024 net sales guidance of $980M-$1.02B and Adjusted EBITDA of $106M-$112M.","Signed agreement to acquire Zoetis' Medicated Feed Additive portfolio to enhance product offerings.","Vaccine sales surged 26% and MFA and other sales increased 16% in the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":744515000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219346,"accession_number":"0001104659-24-058026","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend payable June 26, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend of $0.12 per share on Class A and Class B common stock declared.","Payable on June 26, 2024; record date is June 5, 2024.","Press release issued May 7, 2024 via Business Wire."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219345,"accession_number":"0001104659-24-053265","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Phibro Animal Health acquires Zoetis' medicated feed additive portfolio for $350M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$350M cash purchase; acquired portfolio generated ~$400M revenue in 2023 across 37 product lines.","Six manufacturing sites (four US, one Italy, one China) and >300 Zoetis employees expected to transition.","Deal expected to close H2 2024; Phibro to fund primarily with debt, targeting net leverage 3.5-4.0x at close.","Phibro expects acquisition to boost EBITDA margin and be accretive to adjusted EPS.","Combined pro forma sales ~$1.4B in last twelve months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239177,"accession_number":"0001558370-24-000864","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro reports Q2 diluted EPS of $0.03 on net income of $1.3M; reaffirms adjusted EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $249.9M (+2% YoY); Animal Health segment up 6% led by 31% vaccine growth.","GAAP net income $1.3M, diluted EPS $0.03, down from $7.2M and $0.18 a year ago.","Adjusted EBITDA $29.5M (-5% YoY); adjusted diluted EPS $0.33 (-2%).","FY2024 guidance: reaffirmed adjusted EBITDA $106-$112M; GAAP net income lowered to $12-$17M (down 55%).","Includes $4.2M Brazil employment tax litigation charge and $7.5M foreign currency losses from Argentina devaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":481292000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239176,"accession_number":"0001104659-24-011120","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable March 27","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on March 27, 2024 to stockholders of record on March 6, 2024.","Dividend declared by Board of Directors on February 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239175,"accession_number":"0001104659-24-010954","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Phibro Animal Health appoints Glenn C. David as CFO effective Feb 9, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn C. David, former Zoetis CFO and group president, joins Phibro as CFO starting Feb 9, 2024.","David receives $650K base salary, 50% target bonus, $135K signing bonus, and 300K RSUs (half time-vesting, half performance-vesting).","Performance RSUs vest based on 90-day average stock price from $20 to $60+ over 5 years.","Interim CFO Richard Johnson will stay in advisory role for smooth transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256687,"accession_number":"0001558370-23-018296","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health reports Q1 net loss of $8.0M; lowers FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $231.3M (-1% YoY); net loss $8.0M vs $3.9M net income prior year; diluted loss per share $0.20.","Adjusted EBITDA $18.7M (-16% YoY); adjusted diluted EPS $0.14 (-33%).","Animal Health segment sales up 4% to $160.5M; Mineral Nutrition down 6%; Performance Products down 18%.","FY2024 guidance reduced: net sales $980M-$1.02B, adjusted EBITDA $106M-$112M, adjusted diluted EPS $1.04-$1.16.","Results include $10.4M pension settlement charge, $6.7M FX losses; Israel conflict causing manufacturing disruptions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":231349000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256686,"accession_number":"0001104659-23-115253","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Phibro Animal Health shareholders reelect three Class I directors and ratify PwC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["99.3% of voting power represented; Daniel M. Bendheim, Jonathan Bendheim, Sam Gejdenson elected to serve until 2026.","Director votes: Bendheim ~210.8M for, Bendheim ~210.4M for, Gejdenson ~206.7M for; 475k broker non-votes each.","Ratification of PwC as independent auditor for fiscal 2024 passed with 219.5M votes for, 878k against, 6.8k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256685,"accession_number":"0001104659-23-115093","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Phibro Animal Health faces FDA actions to revoke Mecadox approval; $20M sales at risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued final order revoking approved method for detecting carbadox residues in swine.","FDA proposed to withdraw all new animal drug applications for Mecadox in swine feed; Phibro may request hearing.","Mecadox sales for fiscal year ended June 30, 2023 were approximately $20 million.","Phibro states it is extremely disappointed, believes in safety, and will defend Mecadox's continued use.","Company notes 50+ year history of safe use and intends to take appropriate action against FDA's steps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256684,"accession_number":"0001104659-23-114765","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable Dec. 20, 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on December 20, 2023, to stockholders of record on November 29, 2023.","No change to dividend rate from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274056,"accession_number":"0001104659-23-098303","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Phibro Animal Health CFO Damian Finio resigns; Richard Johnson named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Damian Finio resigns as CFO effective September 29, 2023.","Richard G. Johnson, former CFO (2002-2020), appointed interim CFO effective September 30, 2023.","Johnson has served as Finance Advisor since 2020 and will assist with transition until a successor is found.","No family relationships or reportable transactions involving Johnson under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274055,"accession_number":"0001558370-23-015362","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Q4 adj diluted EPS up 5% to $0.38; full-year net income down 34%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $255.0M (flat YoY); net income $11.5M (+54%); adj diluted EPS $0.38 (+5%).","FY2023 net sales $977.9M (+4%); net income $32.6M (-34%); adj diluted EPS $1.21 (-8%).","FY2024 guidance: net sales $1.0-1.05B; adj EBITDA $115-121M; adj diluted EPS $1.12-1.27.","Animal Health FY sales +9% to $659.9M; Mineral Nutrition -6%; gross leverage 4.2x.","Free cash flow negative $24M; liquidity $248M; pension settlement to incur ~$10.4M expense in Q1 FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274054,"accession_number":"0001104659-23-083855","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable Sept 27","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock declared.","Payable on September 27, 2023, to stockholders of record as of September 6, 2023.","Dividend is consistent with prior quarter's rate; no change announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274053,"accession_number":"0001104659-23-078746","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Phibro Animal Health grants COO 300k performance RSUs and $4.25M cash retention award","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["COO Larry Miller gets 300k performance RSUs; vesting tied to 90-day avg stock price ($20-$60+) by June 30, 2027.","Maximum vesting 100% at $60+ average; no vesting if below $20.","Retention cash award of $4.25M (LTIP) payable in four equal installments starting June 30, 2024.","Mr. Miller will not receive additional equity grants before Dec 31, 2025.","Accelerated vesting provisions on qualified termination or change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291217,"accession_number":"0001104659-23-072253","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Phibro Animal Health enters $50M incremental term loan amendment to credit agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Incurred $50M incremental term loans on June 16, 2023 under amended credit agreement.","Proceeds used to repay revolving credit loans; quarterly payments of $1.25M begin Sep 30, 2023.","Loans mature April 22, 2026; interest rates range from SOFR 2.00% to 2.75% based on leverage.","Amendment adds a pricing grid tier and was executed by required lenders and the administrative agent.","Existing guarantees and collateral continue to secure all obligations under the credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291216,"accession_number":"0001558370-23-007861","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Q3 net income falls 43% to $10.0M; Animal Health sales up 11%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $245.7M (+3% YoY); net income $10.0M (-43%); diluted EPS $0.25 (-43%); adjusted diluted EPS $0.29 (-13%).","Animal Health segment net sales +11% to $164.4M; Mineral Nutrition -9% to $62.9M; Performance Products -17% to $18.3M.","Adjusted EBITDA $27.4M (-2% YoY); free cash flow -$43M trailing twelve months (inventory build of $43M).","Company reiterates FY2023 guidance: net sales $960M-$1B, adjusted diluted EPS $1.21-$1.31.","Management notes recessionary pressure in Mineral Nutrition; opened new autogenous vaccine facility in Brazil."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":722840000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291215,"accession_number":"0001104659-23-054358","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health Declares $0.12 Quarterly Dividend","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock declared on May 1, 2023.","Dividend payable on June 28, 2023, to stockholders of record at close of business on June 7, 2023.","Phibro Animal Health Corporation (Nasdaq:PAHC) announced the dividend via press release on May 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312016,"accession_number":"0001558370-23-001038","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health Q2 net income down 59% to $7.2M; guidance lowered on environmental costs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $244.6M (+5% YoY); GAAP diluted EPS $0.18 vs $0.43 prior; adjusted diluted EPS $0.34 vs $0.37.","Adjusted EBITDA $30.9M (+6% YoY); Animal Health segment grew 9% while Mineral Nutrition declined 8%.","Recorded $6.6M environmental remediation cost from tentative settlement of California contamination lawsuit.","Updated FY23 guidance: Net income lowered to $34-38M (from $39-43M); adjusted metrics unchanged.","Free cash flow -$45M over trailing 12 months due to inventory build to mitigate supply chain risk."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":477167000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312015,"accession_number":"0001104659-23-011197","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Phibro Animal Health appoints Alejandro Bernal to board, declares $0.12 quarterly dividend","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Alejandro Bernal as independent Class III director, effective February 6, 2023.","Bernal is CEO of PetDx and former President of Mars Veterinary Health International and Global Diagnostics.","Board size increases to 9, with 6 independent directors.","Declared quarterly cash dividend of $0.12 per share, payable March 22, 2023 to holders of record March 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330600,"accession_number":"0001558370-22-017185","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Q1 net income down 41% to $3.9M; lowers FY2023 EPS guidance due to rates, tax","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $232.5M (+8% YoY); diluted EPS $0.10 (-41%); adjusted diluted EPS $0.21 (-18%).","Animal Health segment sales $154.9M (+10%); Mineral Nutrition $59.6M (+10%).","FY2023 guidance: net sales $960M-$1B and adjusted EBITDA $113-$118M (unchanged).","FY2023 diluted EPS guidance cut to $0.96-$1.06 from $1.11-$1.21; adjusted EPS to $1.21-$1.31 from $1.28-$1.38.","Adjusted effective tax rate guidance raised to 33% from 30% due to foreign tax credit regulations."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":232521000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330599,"accession_number":"0001104659-22-115975","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Phibro Animal Health annual meeting results: all proposals approved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Jack C. Bendheim and E. Thomas Corcoran elected as Class III directors with >206M and >216M votes for.","Advisory vote on executive compensation approved with 218.9M for, 725K against, 203K abstained.","Ratification of PricewaterhouseCoopers as auditor for FY2023 approved with 218.7M for, 1.8M against, 178K abstained.","Total voting power represented at meeting was 99.4% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330598,"accession_number":"0001104659-22-115453","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend payable Dec 21, 2022","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Dividend payable on December 21, 2022 to holders of record on November 30, 2022.","Board of Directors declared the dividend on November 7, 2022.","No change in dividend rate from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-07T23:59:59+00:00|330598"}